發(fā)布時(shí)間：2018-02-08 20:25

  本文關(guān)鍵詞： 利福平注射液 口服利福平 肺結(jié)核 Meta分析 療效 安全性　出處：《中國(guó)藥房》2015年15期 　論文類(lèi)型：期刊論文

【摘要】：目的:系統(tǒng)評(píng)價(jià)不同劑型利福平對(duì)比治療肺結(jié)核的療效和安全性,以為臨床治療提供循證參考。方法:計(jì)算機(jī)檢索Ovid-medline、Pub Med、EMBase、Cochrane圖書(shū)館、相關(guān)期刊論文、中文科技期刊數(shù)據(jù)庫(kù)、萬(wàn)方數(shù)據(jù)庫(kù)和相關(guān)網(wǎng)站,收集利福平注射液(試驗(yàn)組)對(duì)比利福平膠囊/片劑(對(duì)照組)治療肺結(jié)核的隨機(jī)對(duì)照試驗(yàn)(RCT),提取資料并進(jìn)行質(zhì)量評(píng)價(jià)后,采用Rev Man 5.2統(tǒng)計(jì)軟件進(jìn)行Meta分析。結(jié)果:共納入18項(xiàng)RCT,合計(jì)1 646例患者。Meta分析結(jié)果顯示,試驗(yàn)組患者痰菌轉(zhuǎn)陰率[初治RR=1.20,95%CI(1.12,1.27),P0.000;復(fù)治RR=1.23,95%CI(1.04,1.46),P=0.02;繼發(fā)RR=1.23,95%CI(1.12,1.34),P0.000]和病灶吸收率[初治RR=1.18,95%CI(1.10,1.26),P0.000;復(fù)治RR=1.37,95%CI(1.03,1.82),P=0.03;繼發(fā)RR=1.20,95%CI(1.11,1.31),P0.000]均顯著優(yōu)于對(duì)照組,兩組比較差異均有統(tǒng)計(jì)學(xué)意義;兩組患者肝功能異常發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義[RR=0.98,95%CI(0.78,1.23),P=0.86]。結(jié)論:利福平注射液治療初治、復(fù)治、繼發(fā)性肺結(jié)核的療效顯著優(yōu)于口服劑型,安全性相當(dāng)。由于納入研究質(zhì)量一般,該結(jié)論有待大樣本、高質(zhì)量的RCT進(jìn)一步驗(yàn)證。
[Abstract]:Objective: To evaluate the efficacy and safety of different dosage of contrast of rifampicin in the treatment of pulmonary tuberculosis, in order to provide references for clinical evidence-based. Methods: We searched Ovid-medline, Pub Med, EMBase, Cochrane library, Chinese CNKI, Chinese journals database, Wanfang database and related website, Rifampicin Injection collection (test group) Rifampicin Capsules / tablet (control group) randomized controlled trials for treatment of pulmonary tuberculosis (RCT), and evaluate the quality of extracted data, using Rev Man 5.2 statistical software for Meta analysis. Results: 18 RCT were included, with a total of 1646 cases of.Meta analysis results showed that the test group the sputum negative conversion rate of early treatment of RR=1.20,95%CI (1.12,1.27), P0.000 RR=1.23,95%CI (1.04,1.46); retreatment, P=0.02; secondary RR=1.23,95%CI (1.12,1.34), P0.000] and lesions absorption rate [untreated RR=1.18,95%CI (1.10,1.26), P0.000 complex; Treatment of RR=1.37,95%CI (1.03,1.82), P=0.03 RR=1.20,95%CI (1.11,1.31); secondary, P0.000] were significantly better than the control group, the two groups there were statistically significant differences between the two groups of patients with abnormal liver function; there were no significant differences in [RR=0.98,95%CI (0.78,1.23), P =0.86]. conclusion: Rifampicin Injection for the initial treatment, relapse, treatment of secondary pulmonary tuberculosis superior oral dosage, safety. Due to the quality of the included studies, this conclusion needs large sample, high quality RCT was further validated.

【作者單位】： 河南省胸科醫(yī)院藥劑科;
【基金】：國(guó)家科技支撐計(jì)劃課題(No.2013BAI06B04)
【分類(lèi)號(hào)】：R521

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 翟廣;李波;李玉芹;劉亞男;寇長(zhǎng)貴;姚燕;趙書(shū)欣;;利福噴丁與利福平治療肺結(jié)核療效和安全性的Meta分析[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2011年03期

2 薛笑甜;;利福平注射液治療初治菌陽(yáng)肺結(jié)核的療效及安全性評(píng)價(jià)[J];吉林醫(yī)學(xué);2012年18期

3 黃\敲，

本文編號(hào)：1496195